Exhibit 99.2
LETTER TO EMPLOYEES
| | |
| TO: | | Crown Laboratories Employees |
| FROM: | | Jeff Bedard, Founder and Chief Executive Officer; Nadeem Moiz, President, Chief Operating Officer and Chief Financial Officer |
| DATE: | | December 9, 2024 |
| RE: | | All Hands Company Update |
Hello Crown Team,
We are excited to announce that we have reached a revised deal with Revance Therapeutics. This marks a significant step forward in the planned merger of the two companies and great progress in our collective pursuit of becoming one of the leading global aesthetics and skincare companies. We expect to commence a tender offer to acquire all outstanding shares of Revance’s common stock later this month. Completion of the transaction is expected early 2025, subject to Revance stockholders validly tendering shares representing at least a majority of the voting power of Revance, and other customary closing conditions. We look forward to sharing more information at a company-wide all-hands meeting this afternoon.
We would like to thank all of you who have helped in our integration planning process thus far and with a revised deal in place, we look forward to your support with more comprehensive integration planning to follow in the coming weeks. At the same time, please remember that until the transaction officially closes, Crown and Revance will continue to operate as two separate companies. It is essential that we continue to provide superb support to our customers and finish the year strong. We look forward to growing the combined organization into a global leader in aesthetics and skincare.
Best,
Jeff and Nadeem
####
Forward-Looking Statements
Certain statements contained in this communication are “forward-looking statements.” The use of words such as “anticipates,” “hopes,” “may,” “should,” “intends,” “projects,” “estimates,” “expects,” “plans” and “believes,” among others, generally identify forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, among others, statements relating to Revance Therapeutics, Inc. (“Revance”) and Crown Laboratories, Inc. (“Crown”), their future financial performance, business prospects and strategy, expectations with respect to the tender offer and the merger, including the timing thereof and Revance’s and Crown’s ability to successfully complete such transactions and realize the anticipated benefits. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the tender offer and the merger, including, among other things, regarding how many of Revance stockholders will tender their shares in the tender offer, the possibility that competing offers will be made, the ability to satisfy the conditions to the closing of the tender offer and the merger, the expected timing of the tender offer and the merger, the possibility that the merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties’ operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the announcement of the tender offer and the merger on Revance’s and Crown’s business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of Revance and Crown, and
